Mandate

Vinge has advised Sparbanken Skåne

August 14, 2017

Vinge acted as legal adviser in connection with Sparbanken Skåne AB (publ)’s (”Sparbanken Skåne”) establishment of a programme for the issuance of covered bonds in accordance with the Swedish Covered Bonds Issuance Act (SFS 2003:1223).

The programme enables Sparbanken Skåne to continuously issue notes in SEK within a maximum outstanding nominal amount of SEK 30 billion at each time. The borrowing through covered bonds will enable Sparbanken Skåne to increase its presence on the capital market and to diversify its borrowing.

Vinge’s team consisted of partner Louise Brorsson Salomon together with amongst others Josefine Larsson, André Isacson, Lionardo Ojeda and Sara Osman.

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024